...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith presents at BIO Investor Forum Oct 17th

Looks like Mr. Ken Lebioda and Dr. Sanjay Lakhotia gave the presentations today for Resverlogix and Zenith, respectively (according to the company presentation schedule on the BIO Investor Forum web site). I don't see either slide deck on the company web pages though. Perhaps too close to the AGM just a month prior to expect anything new. 

BearDownAZ 

Share
New Message
Please login to post a reply